Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Core Viewpoint - Novo Nordisk plans to reduce the monthly list prices of its obesity and diabetes drugs by up to 50% starting in 2027 to enhance accessibility for insured patients [1][5] Pricing Strategy - The new lower list price for the obesity injection Wegovy, the diabetes shot Ozempic, and the oral diabetes drug Rybelsus will be $675 per month starting January 1, 2027, down from approximately $1,350 and $1,027 respectively [2] - This price cut specifically targets insured patients whose out-of-pocket costs are linked to list prices, such as those with high-deductible health plans or co-insurance benefit designs [3] Competitive Landscape - The price reduction is a strategic move to enhance competitiveness against Eli Lilly, which currently holds a majority share in the GLP-1 market and has not significantly lowered its U.S. list prices [4] - Eli Lilly's earlier entry into the direct-to-consumer market and the effectiveness of its drugs have allowed it to lead in this space [4] Market Demand - There is a clear demand from private and public payers, as well as patients, for lower list prices, which Novo Nordisk aims to address with this initiative [5]